Literature summary for 3.4.15.1 extracted from

McMurray, J.J.; Young, J.B.; Dunlap, M.E.; Granger, C.B.; Hainer, J.; Michelson, E.L.; Earle, S.; Olofsson, B.; Ostergren, J.; Yusuf, S.; Swedberg, K.; Pfeffer, M.A.; Pfeffer, M.A.
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM)-added trial (2006), Am. Heart J., 151, 985-991.

Search for more literature for 3.4.15.1

Application

Application	Comment	Organism
medicine	combined use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers improves outcomes in patients with heart failure more than an evidence-based dose of angiotensin-converting enzyme inhibitor alone	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)